News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
677,604 Results
Type
Article (58494)
Company Profile (328)
Press Release (618782)
Section
Business (191057)
Career Advice (2743)
Deals (34693)
Drug Delivery (106)
Drug Development (83101)
Employer Resources (159)
FDA (17250)
Job Trends (15176)
News (336935)
Policy (35961)
Tag
Academia (2840)
Africa (939)
Alliances (49392)
Alzheimer's disease (1248)
Approvals (17168)
Arizona (150)
Artificial intelligence (84)
Asia (41234)
Australia (7069)
Bankruptcy (344)
Best Places to Work (11467)
Biosimilars (71)
Biotechnology (232)
C2C Services and Suppliers (70806)
California (2029)
Canada (945)
Cancer (606)
Career advice (2305)
Cell therapy (155)
China (162)
Clinical research (64882)
Collaboration (188)
Colorado (86)
Compensation (86)
Connecticut (85)
COVID-19 (2712)
Cystic fibrosis (82)
Data (428)
Diabetes (100)
Diagnostics (6083)
Drug pricing (94)
Earnings (69060)
Employer resources (140)
Europe (94453)
Events (100072)
Executive appointments (175)
FDA (17529)
Florida (289)
Funding (178)
Gene therapy (116)
GLP-1 (615)
Government (4616)
Healthcare (19233)
Hotbed/Location (446369)
Illinois (281)
Indiana (159)
Infectious disease (2751)
Inflammatory bowel disease (101)
Interviews (508)
IPO (15963)
Job creations (3912)
Job search strategy (1928)
Kansas (88)
Layoffs (459)
Legal (8538)
Lung cancer (131)
Manufacturing (113)
Maryland (434)
Massachusetts (1625)
Medical device (13438)
Medtech (13443)
Mergers & acquisitions (18626)
Metabolic disorders (317)
Michigan (131)
Minnesota (217)
Neuroscience (1440)
New Jersey (623)
New York (618)
NextGen Class of 2024 (6816)
Non-profit (4623)
North Carolina (655)
Northern California (879)
Obesity (191)
Ohio (110)
Opinion (229)
Patents (82)
Pennsylvania (579)
People (57171)
Phase I (19879)
Phase II (28226)
Phase III (21669)
Pipeline (126)
Policy (73)
Postmarket research (3026)
Preclinical (8596)
Press Release (71)
Radiopharmaceuticals (247)
Rare diseases (158)
Real estate (5858)
Regulatory (23901)
Research institute (2532)
Resumes & cover letters (443)
South America (1300)
Southern California (815)
Startups (3633)
Texas (263)
United States (9101)
Vaccines (577)
Washington State (255)
Weight loss (179)
Date
Last 7 days (581)
Last 30 days (2544)
Last 365 days (37877)
2024 (27681)
2023 (41039)
2022 (52164)
2021 (56654)
2020 (55101)
2019 (47791)
2018 (36236)
2017 (34186)
2016 (33394)
2015 (37936)
2014 (30655)
2013 (25613)
2012 (27435)
2011 (28165)
2010 (26096)
677,604 Results for "esteve s a laboratorios del dr esteve s a".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Pharm Country
ESTEVE Launches INBRIJA® in Spain
Acorda Therapeutics, Inc. announced that Esteve Pharmaceuticals, S.A. has launched INBRIJA 33 mg in Spain.
March 7, 2023
·
5 min read
Business
Alvotech and Dr. Reddy’s enter into collaboration for commercialization of AVT03 (denosumab), a biosimilar candidate to Prolia® & Xgeva® in the U.S., Europe and UK
Alvotech (NASDAQ: ALVO) and Dr. Reddy’s Laboratories SA, wholly-owned subsidiary of Dr. Reddy’s Laboratories Ltd., (BSE: 500124 | NSE: DRREDDY | NYSE: RDY | NSEIFSC: DRREDDY, along with its subsidiaries hereafter referred to as “Dr. Reddy’s”), today announced that the companies have entered into a license and supply agreement for the commercialization of AVT03, Alvotech’s biosimilar candidate to Prolia® and Xgeva® (denosumab).
May 21, 2024
·
14 min read
Pharm Country
Finacity Facilitates MXN 1 Billion Securitization for Laboratorios Sanfer, S.A. de C.V.
Finacity Corporation announced that it has successfully launched a trade receivables securitization for Laboratorios Sanfer, S.A. de C.V.
December 15, 2023
·
2 min read
Business
Alvotech and Dr. Reddy’s Enter Into Collaboration for Commercialization of AVT03 (denosumab), a Biosimilar Candidate to Prolia® & Xgeva® in the U.S., Europe and UK
Alvotech and Dr. Reddy’s Laboratories today announced that the companies have entered into a license and supply agreement for the commercialization of AVT03, Alvotech’s biosimilar candidate to Prolia® and Xgeva® (denosumab).
May 21, 2024
·
14 min read
Aurigene Pharmaceutical Services Ltd., and Vipergen announce a strategic partnership for offering DNA encoded library (DEL) screening and integrated drug discovery services.
Aurigene Pharmaceutical Services Ltd. (Aurigene), a global contract research, development, and manufacturing services organization (CRDMO), and Vipergen ApS, a niche small-molecule drug discovery service provider specialized in DEL technologies, entered into a strategic partnership.
April 19, 2024
·
3 min read
Pharm Country
Esteve Launches INBRIJA® in Germany
Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that Esteve Pharmaceuticals GmbH has launched INBRIJA ® 33 mg (levodopa inhalation powder, hard capsules) in Germany.
June 16, 2022
·
5 min read
Dr. Reddy’s Laboratories Announces the Launch of Doxycycline Capsules, 40 mg* in the U.S.
Dr. Reddy’s Laboratories Ltd. today announced its launch of Doxycycline Capsules, 40 mg* in the U.S. market, a therapeutic generic equivalent of ORACEA® (doxycycline, USP) Capsules, 40 mg approved by the U.S. Food and Drug Administration (USFDA).
May 3, 2024
·
3 min read
Press Releases
SEED Therapeutics Appoints Eisai Co., Ltd.’s Dr. Yoshiharu Mizui to Board of Directors
September 12, 2024
·
2 min read
Business
Dr. Reddy’s Q4 & Full Year FY24 Financial Results
Dr. Reddy’s Laboratories Ltd. (BSE: 500124 | NSE: DRREDDY | NYSE: RDY | NSEIFSC: DRREDDY) today announced its consolidated financial results for the fourth quarter and full year ended March 31, 2024.
May 7, 2024
·
21 min read
Business
Nyxoah Appoints Dr. Maurits S. Boon, MD as Chief Medical Officer
Nyxoah SA, a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea, announced the appointment of Dr. Maurits S. Boon, MD as Chief Medical Officer.
April 11, 2024
·
5 min read
1 of 67,761
Next
